Compare URBN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | MIRM |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.2B |
| IPO Year | 1995 | 2019 |
| Metric | URBN | MIRM |
|---|---|---|
| Price | $82.41 | $86.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $89.43 | ★ $145.79 |
| AVG Volume (30 Days) | ★ 923.1K | 695.4K |
| Earning Date | 11-24-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.78 | ★ 74.59 |
| EPS | ★ 4.06 | N/A |
| Revenue | ★ $6,165,376,000.00 | $19,138,000.00 |
| Revenue This Year | $9.51 | $33.62 |
| Revenue Next Year | $6.94 | $17.65 |
| P/E Ratio | $19.94 | ★ N/A |
| Revenue Growth | ★ 11.07 | N/A |
| 52 Week Low | $59.54 | $63.23 |
| 52 Week High | $85.43 | $130.00 |
| Indicator | URBN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 63.92 | 43.77 |
| Support Level | $73.34 | $73.82 |
| Resistance Level | $84.89 | $98.03 |
| Average True Range (ATR) | 2.09 | 3.66 |
| MACD | 0.62 | -0.10 |
| Stochastic Oscillator | 97.59 | 59.18 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates approximately 800 stores and e-commerce platforms in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily appeals to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.